arrow
S

Sue Charlton

UK Health Security Agency
H指数:26
被引数:1.5万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Searching for immune correlates in Lassa vaccine development – workshop report

寻找拉沙热疫苗开发中的免疫相关性——研讨会报告

2026-05-040
OAAI
Heterologous COVID-19 vaccine schedule with protein-based prime (NVX-CoV2373) and mRNA boost (BNT162b2) induces strong humoral responses: Results from COV-BOOST trial

蛋白为基础的初次免疫(NVX-CoV2373)与mRNA加强免疫(BNT162b2)的异源COVID-19疫苗接种方案可诱导强烈的体液免疫反应:COV-BOOST试验结果

2025-08-070
OAAI
Persistence of immune response in heterologous COVID vaccination schedules in the Com-COV2 study-A single-blind, randomised trial incorporating mRNA, viral-vector and protein-adjuvant vaccines

Com-COV2研究中异源COVID疫苗接种计划中免疫反应的持久性-一项纳入mRNA,病毒载体和蛋白质佐剂疫苗的单盲,随机试验

2023-06-017
OAAI
Persistence of the immune response after two doses of ChAdOx1 nCov-19 (AZD1222): 1 year of follow-up of two randomized controlled trials

两剂ChAdOx1 nCov-19 (AZD1222) 后免疫反应的持续性: 两项随机对照试验的1年随访

2023-02-028
OAAI
Effect of priming interval on reactogenicity, peak immunological response, and waning after homologous and heterologous COVID-19 vaccine schedules: exploratory analyses of Com-COV, a randomised control trial

接种间隔对同源与异源新型冠状病毒肺炎疫苗接种程序的反应原性、免疫应答峰值及衰减的影响:Com-COV随机对照试验的探索性分析

2022-11-0126
OAAI
Safety, immunogenicity, and reactogenicity of BNT162b2 and mRNA-1273 COVID-19 vaccines given as fourth-dose boosters following two doses of ChAdOx1 nCoV-19 or BNT162b2 and a third dose of BNT162b2 (COV-BOOST): a multicentre, blinded, phase 2, randomised trial

BNT162b2和mRNA-1273新型冠状病毒肺炎疫苗在两剂ChAdOx1 nCoV-19或BNT162b2和第三剂BNT162b2 (cov-boost) 后作为第四剂加强剂的安全性,免疫原性和反应原性: 多中心,盲法,2期随机试验

2022-08-01114
OAAI
Persistence of immunogenicity after seven COVID-19 vaccines given as third dose boosters following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK: Three month analyses of the COV-BOOST trial

在英国,在两剂ChAdOx1 nCov-19或BNT162b2之后,作为第三剂加强剂给予七种新型冠状病毒肺炎疫苗后的免疫原性持久性: cov-boost试验的三个月分析

2022-06-0147
OAAI
Immunogenicity, safety, and reactogenicity of heterologous COVID-19 primary vaccination incorporating mRNA, viral-vector, and protein-adjuvant vaccines in the UK (Com-COV2): a single-blind, randomised, phase 2, non-inferiority trial

在英国 (Com-COV2),掺入mRNA,病毒载体和蛋白质佐剂疫苗的异源新型冠状病毒肺炎初次疫苗接种的免疫原性,安全性和反应原性: 一项单盲,随机,2期,非劣效性试验

LANCET
IF88.5
2022-01-01169
OAAI
Structures and therapeutic potential of anti-RBD human monoclonal antibodies against SARS-CoV-2

抗RBD人单克隆抗体的结构和治疗SARS-CoV-2的潜力

2022-01-018
OAAI
Immunological and pathological outcomes of SARS-CoV-2 challenge following formalin-inactivated vaccine in ferrets and rhesus macaques
2021-09-1018
OAAI
Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trial

腺病毒载体和mRNA新型冠状病毒肺炎疫苗 (com-cov) 的异源与同源初免方案的安全性和免疫原性: 一项单盲,随机,非劣效性试验

LANCET
IF88.5
2021-09-01374
OAAI
ChAdOx1 nCoV-19 protection against SARS-CoV-2 in rhesus macaque and ferret challenge models
2021-07-2615
OAAI
Quantification of SARS-CoV-2 neutralizing antibody by wild-type plaque reduction neutralization, microneutralization and pseudotyped virus neutralization assays
2021-04-23183
OAAI
Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial

ChAdOx1 nCoV-19 (AZD1222) 疫苗对SARS-CoV-2相关变异202012/01 (B.1.1.7) 的疗效: 一项随机对照试验的探索性分析

LANCET
IF88.5
2021-04-01410
OAAI
Comparison of rhesus and cynomolgus macaques as an infection model for COVID-19
2021-02-24115
OAAI
Dose-dependent response to infection with SARS-CoV-2 in the ferret model and evidence of protective immunity
2021-01-04129
OAAI
Antiviral Screening of Multiple Compounds against Ebola Virus
2016-10-2737
OAAI